Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. https://t.co/7eWuUzgLbQ https://t.co/e34K4gYFV3
Open Access UCL Research: Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors https://t.co/6bkwSS8io0
RT @NCICancerBio: In a study funded by our division, @gouthamnarla @UMich et al. found that a frequent #mutation in the scaffolding subunit…
RT @NCICancerBio: In a study funded by our division, @gouthamnarla @UMich et al. found that a frequent #mutation in the scaffolding subunit…
In a study funded by our division, @gouthamnarla @UMich et al. found that a frequent #mutation in the scaffolding subunit of the #PP2A phosphatase inhibits its tumor suppressor activity and promotes resistance to MEK inhibitors @oncogenejournal https://t.c
RT @gouthamnarla: Very proud of our work and #pharmacocaitlin for leadings these efforts also thanks to the NCI for their support throughou…
RT @gouthamnarla: Very proud of our work and #pharmacocaitlin for leadings these efforts also thanks to the NCI for their support throughou…
RT @gouthamnarla: Very proud of our work and #pharmacocaitlin for leadings these efforts also thanks to the NCI for their support throughou…
RT @gouthamnarla: Very proud of our work and #pharmacocaitlin for leadings these efforts also thanks to the NCI for their support throughou…
@a_dimambro @MariaTeresaEs
RT @gouthamnarla: Very proud of our work and #pharmacocaitlin for leadings these efforts also thanks to the NCI for their support throughou…
RT @gouthamnarla: Very proud of our work and #pharmacocaitlin for leadings these efforts also thanks to the NCI for their support throughou…
RT @gouthamnarla: Very proud of our work and #pharmacocaitlin for leadings these efforts also thanks to the NCI for their support throughou…
Very proud of our work and #pharmacocaitlin for leadings these efforts also thanks to the NCI for their support throughout this process
RT @pharmacocaitlin: Part of my thesis work is now officially out in this week's issue of @oncogenejournal! Extremely grateful for all of o…
Congratulations!
RT @pharmacocaitlin: Part of my thesis work is now officially out in this week's issue of @oncogenejournal! Extremely grateful for all of o…
RT @pharmacocaitlin: Part of my thesis work is now officially out in this week's issue of @oncogenejournal! Extremely grateful for all of o…
RT @RitaGTohmePhD: Geat work by @pharmacocaitlin! https://t.co/0e7dfJgCH3
Geat work by @pharmacocaitlin!
RT @pharmacocaitlin: Part of my thesis work is now officially out in this week's issue of @oncogenejournal! Extremely grateful for all of o…
RT @pharmacocaitlin: Part of my thesis work is now officially out in this week's issue of @oncogenejournal! Extremely grateful for all of o…
RT @pharmacocaitlin: Part of my thesis work is now officially out in this week's issue of @oncogenejournal! Extremely grateful for all of o…
Part of my thesis work is now officially out in this week's issue of @oncogenejournal! Extremely grateful for all of our co-authors and collaborators! Check it out 👩🔬😀 @NarlaLabUMich https://t.co/EmljoFC4oY
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors https://t.co/trLGdnYykL #oncology- basic science #feedly
RT @pharmacocaitlin: Our work on understanding how a recurrent mutation to PP2A impacts response to MEK inhibitors is online today @oncogen…
RT @oncogenejournal: Amazing work by @pharmacocaitlin and colleagues now #online #Cancer #CancerResearch #NEW https://t.co/08nOkYBUPy
RT @oncogenejournal: Amazing work by @pharmacocaitlin and colleagues now #online #Cancer #CancerResearch #NEW https://t.co/08nOkYBUPy
Amazing work by @pharmacocaitlin and colleagues now #online #Cancer #CancerResearch #NEW
RT @pharmacocaitlin: Our work on understanding how a recurrent mutation to PP2A impacts response to MEK inhibitors is online today @oncogen…
RT @AbbeyLPerl: Check out the amazing work from my lab posted today in @oncogenejournal. Congrats to @pharmacocaitlin and all my colleagues…
RT @gouthamnarla: Congrats to our amazing research team for this collaborative project published in oncogene today https://t.co/8lfbDiF4D9
RT @pharmacocaitlin: Our work on understanding how a recurrent mutation to PP2A impacts response to MEK inhibitors is online today @oncogen…
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. https://t.co/U6bvOUQkp8
RT @pharmacocaitlin: Our work on understanding how a recurrent mutation to PP2A impacts response to MEK inhibitors is online today @oncogen…
RT @gouthamnarla: Congrats to our amazing research team for this collaborative project published in oncogene today https://t.co/8lfbDiF4D9
RT @gouthamnarla: Congrats to our amazing research team for this collaborative project published in oncogene today https://t.co/8lfbDiF4D9
Check out the amazing work from my lab posted today in @oncogenejournal. Congrats to @pharmacocaitlin and all my colleagues who contributed!
RT @gouthamnarla: Congrats to our amazing research team for this collaborative project published in oncogene today https://t.co/8lfbDiF4D9
Congrats to our amazing research team for this collaborative project published in oncogene today
https://t.co/qabT0wHO3b So proud of our research team and especially Caitlin O'Connor for discovering a new mechanism involving PP2A inactivation driving resistance to kinase inhibitors https://t.co/wmRnh3n7ie
RT @pharmacocaitlin: Our work on understanding how a recurrent mutation to PP2A impacts response to MEK inhibitors is online today @oncogen…
Great work by @pharmacocaitlin!
RT @pharmacocaitlin: Our work on understanding how a recurrent mutation to PP2A impacts response to MEK inhibitors is online today @oncogen…
RT @pharmacocaitlin: Our work on understanding how a recurrent mutation to PP2A impacts response to MEK inhibitors is online today @oncogen…
RT @pharmacocaitlin: Our work on understanding how a recurrent mutation to PP2A impacts response to MEK inhibitors is online today @oncogen…
RT @pharmacocaitlin: Our work on understanding how a recurrent mutation to PP2A impacts response to MEK inhibitors is online today @oncogen…
Our work on understanding how a recurrent mutation to PP2A impacts response to MEK inhibitors is online today @oncogenejournal! Thank you to all of our collaborators who made this work possible! @shozeb_haider @westermarcklab @DiFeoLab @NarlaLabUMich http